Catalent’s Bloomington Plant Making Novo Nordisk’s Obesity Drug Faces FDA Scrutiny Regarding Drug Manufacturing Concerns – Catalent (NYSE:CTLT)
Novo Nordisk A/S NVO has encountered manufacturing challenges and drug shortages for its diabetes and weight loss drugs due to unprecedented demand for Wegvoy and Ozempic. To manage the shortage, Novo Nordisk agreed to…